China, the second largest pharmaceutical market in the world (valued at more than $150 billion),  is experiencing a paradigm shift characterized by a booming economy, a growing middle class, and an increasingly aged population with rising disease rates. By reviewing recent changes to the Chinese pricing and market access landscape, PRECISIONadvisors’ Andrea Ong and Laura Montani discuss how manufacturers can capitalise on this booming market.

Click here to read the full report!